TY - JOUR
T1 - EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
AU - Nagy, György
AU - Roodenrijs, Nadia M T
AU - Welsing, Paco M J
AU - Kedves, Melinda
AU - Hamar, Attila
AU - van der Goes, Marlies C
AU - Kent, Alison
AU - Bakkers, Margot
AU - Pchelnikova, Polina
AU - Blaas, Etienne
AU - Senolt, Ladislav
AU - Szekanecz, Zoltan
AU - Choy, Ernest H
AU - Dougados, Maxime
AU - Jacobs, Johannes Wg
AU - Geenen, Rinie
AU - Bijlsma, Johannes Wj
AU - Zink, Angela
AU - Aletaha, Daniel
AU - Schoneveld, Leonard
AU - van Riel, Piet
AU - Dumas, Sophie
AU - Prior, Yeliz
AU - Nikiphorou, Elena
AU - Ferraccioli, Gianfranco
AU - Schett, Georg
AU - Hyrich, Kimme L
AU - Mueller-Ladner, Ulf
AU - Buch, Maya H
AU - McInnes, Iain B
AU - van der Heijde, Désirée
AU - van Laar, Jacob M
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2022
PY - 2022/1/1
Y1 - 2022/1/1
N2 - OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA).METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A-D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0-10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members.RESULTS: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4-9.6).CONCLUSIONS: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
AB - OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA).METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A-D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0-10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members.RESULTS: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4-9.6).CONCLUSIONS: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
KW - arthritis
KW - fibromyalgia
KW - inflammation
KW - rheumatoid
KW - ultrasonography
UR - http://www.scopus.com/inward/record.url?scp=85122302204&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2021-220973
DO - 10.1136/annrheumdis-2021-220973
M3 - Article
C2 - 34407926
SN - 0003-4967
VL - 81
SP - 20
EP - 33
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 1
ER -